Patents Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
-
Publication number: 20250147046Abstract: Methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides that are or that include epitopes identified by the methods, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with the peptides or vectors and engineered T cells expressing T-cell receptors recognizing the peptides. Also, the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of the peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.Type: ApplicationFiled: January 25, 2023Publication date: May 8, 2025Applicants: ERVIMMUNE, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Stéphane DEPIL, Vincent ALCAZER
-
Patent number: 12285433Abstract: The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.Type: GrantFiled: May 23, 2019Date of Patent: April 29, 2025Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE LAVALInventors: Manuel Rosa-Calatrava, Olivier Terrier, Claire Nicolas De Lamballerie, Guy Boivin, Mario Andres Pizzorno
-
Patent number: 12281319Abstract: The disclosure is directed at providing molecular tools and methods for transgenes integration in the genome of host cells, in particular tools and method enabling a transposition-dependent expression of the transgene, thereby facilitating identification and selection of effectively transformed hosts.Type: GrantFiled: May 17, 2019Date of Patent: April 22, 2025Assignees: SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean Livet, Takuma Kumamoto, Raphaëlle Barry-Martinet, Samuel Tozer, Franck Maurinot, Karine Loulier-Le Franc, Mickaël Le, Stéphane Nedelec, Michel Cohen-Tannoudji
-
Patent number: 12274694Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.Type: GrantFiled: April 6, 2023Date of Patent: April 15, 2025Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUEInventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
-
Patent number: 12265084Abstract: The present invention relates to a method for analyzing the platelets present in a blood sample, said method comprises the steps of (a) adding to said sample a ligand which binds to the MCH I coupled to a fluorochrome, (b) measuring the mean fluorescence intensity of the platelets (MFIplatelets) with a flow cytometer and c) measuring the mean “Forward Scatter” parameter (FSC) with said flow cytometer and determining the MFIplatelets/FSC ratio. The invention also relates to an in vitro method for diagnosing a peripheral or central thrombocytopenia in a subject.Type: GrantFiled: July 29, 2019Date of Patent: April 1, 2025Assignees: ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE STRASBOURGInventors: Blandine Maitre, Catherine Angenieux, Henri De La Salle, Christian Gachet
-
Publication number: 20250084420Abstract: RNA interferent (RNAi) molecules that inhibit a PMP22 protein expression and/or activity by targeting exon 5 of a nucleic acid sequence encoding the PMP22 protein, and the prevention and treatment of the Charcot-Marie-Tooth type 1A or 1E diseases in which an adeno-associated virus (AAV) vector including an RNAi molecule is administered.Type: ApplicationFiled: August 2, 2022Publication date: March 13, 2025Applicants: UNIVERSITE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventor: Nicolas TRICAUD
-
Patent number: 12241125Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: April 25, 2024Date of Patent: March 4, 2025Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 12232883Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.Type: GrantFiled: October 25, 2021Date of Patent: February 25, 2025Assignees: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
-
Patent number: 12232843Abstract: The present invention relates to a method for predicting neurodegenerative decline and/or its severity for a patient, especially of cognitive impairment (CI). Strokes and Parkinson's disease are frequently associated with occurrence of long-term cognitive impairment or dementia with still incompletely resolved mechanisms. The discovery of diagnostic and predictive biomarkers thus remains a major challenge. The method of the invention uses radiomics corresponding to texture features extracted from a plurality of previously-acquired medical brain images and correlated with previously-acquired clinical and/or biological data. A classifier is trained beforehand for learning these radiomics, and then operated on radiomics computed from at least one brain image of a patient to generate a score representative of its risks of neurodegenerative decline. By applying this method on a cohort of 160 MCI and non-MCI patients, the inventors show that MCI patients could be early predicted with a mean accuracy of 88%.Type: GrantFiled: March 6, 2019Date of Patent: February 25, 2025Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LILLE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLEInventors: Nacim Betrouni, Régis Bordet
-
Patent number: 12234513Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: April 25, 2024Date of Patent: February 25, 2025Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Medicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 12227807Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: April 25, 2024Date of Patent: February 18, 2025Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 12223700Abstract: Disclosed is an automatic image analysis method that can be used to automatically recognise at least one rare characteristic in an image to be analysed. The method comprises a learning phase during which at least one convolutional neural network is trained to recognise characteristics, a parameter space of dimension n, in which n?2, is constructed from at least one intermediate layer of the network, a presence probability function is determined for each characteristic in the parameter space from a projection of reference images in the parameter space. During a phase of analysing the image to be analysed, the method comprises a step of recognising the at least one rare characteristic in the image to be analysed on the basis of the presence probability function determined for the at least one rare characteristic.Type: GrantFiled: May 7, 2020Date of Patent: February 11, 2025Assignees: Université Brest Bretagne Occidentale, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventor: Gwenolé Quellec
-
Patent number: 12208130Abstract: The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists.Type: GrantFiled: March 14, 2018Date of Patent: January 28, 2025Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE LILLE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLEInventors: Paolo Giacobini, Vincent Prevot
-
Patent number: 12202860Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: GrantFiled: April 3, 2023Date of Patent: January 21, 2025Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
-
Publication number: 20250019771Abstract: A transcriptomic signature based on Human endogenous retroviruses (HERVs) expression to characterize leukemic stem cells. In particular, determining the presence of Leukemic Stem Cells (LSCs) in a patient. In an aspect, determining the presence of, or quantifying, LSCs in a patient. Also, gene-related methods for the identification of high-risk acute myeloid leukemia (AML) patients, methods of predicting response to treatment, methods to evaluate (minimal) residual disease during follow-up, methods to determine relapse risk, and methods of treatment of patients following implementation of the former methods.Type: ApplicationFiled: November 25, 2022Publication date: January 16, 2025Applicants: ERVIMMUNE, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Stéphane DEPIL, Vincent ALCAZER
-
Patent number: 12195437Abstract: The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative stresses.Type: GrantFiled: July 12, 2019Date of Patent: January 14, 2025Assignees: Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier, Ecole Nationale Superieure de Chimie, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Céline Crauste, Espérance Moine, Philippe Brabet, Thierry Durand, Joseph Vercauteren
-
Publication number: 20250011880Abstract: The use of a transcriptomic signature based on HERVs expression to characterize new AML subtypes, and a method to determine to which AML subtype a patient pertains. The method includes providing relationship between the 9 AML sub-types and HERVs characterized by their specific herv_id and their relationship with one of these AML subtypes, determining from a patient cell sample HERVs expression profile, determining which of the 9 AML subtypes is the most represented based on HERV expression in the cell sample, and attributing to the patient the most represented AML subtype among the 9 AML subtypes. The method allows identifying patients with medium good or bad prognosis and treating the same with a cancer therapy against AML.Type: ApplicationFiled: November 25, 2022Publication date: January 9, 2025Applicants: ERVIMMUNE, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Stéphane DEPIL, Vincent ALCAZER
-
Patent number: 12187793Abstract: The present invention relates to a single-domain antibody (sdAb) which binds to the G protein alpha, comprising an amino acid sequence consisting of 3 CDR regions (CDR1 to CDR3) and 4 hinge regions (FR1 to FR4) according to the following formula (I): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (I) and advantageously having a dissociation constant (Kd), measured in FRET, of less than 100 nM.Type: GrantFiled: July 26, 2019Date of Patent: January 7, 2025Assignees: CISCIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Thomas Fabien Michel Roux, Elodie Julie Dupuis, Eric Jacques Christian Trinquet, Mélanie Da Silva, Camille S. Mailhac, Patrick J M Chames, Daniel Baty, Julien Jean-Marius Soule, Philippe Rondard, Jean-Philippe R. Pin
-
Patent number: 12186433Abstract: The present invention concerns modified nucleobases, nucleosides, deoxynucleosides, and/or their derivatives, nanocapsules comprising them, hydrogels and oleogels comprising said nanocapsules or said above-mentioned compounds and their uses, in particular their pharmaceutical uses.Type: GrantFiled: September 7, 2018Date of Patent: January 7, 2025Assignees: Universite D'Angers France, Institut National De La Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire D'Angers Cedex FranceInventors: Marion Pitorre, Guillaume Bastiat, Jérôme Bejaud, Jean-Pierre Benoit
-
Publication number: 20250003980Abstract: Identification of at least one microorganism present in a sample based on the detection of peptides issued from the cleavage of ribosomal proteins of said microorganism, comprising lysis of microorganism(s) and cleavage of the proteins, obtaining a mixture of peptides, decomplexing the peptide mixture using a liquid separation device coupled with a mass spectrometer, nebulizing the liquid to produce an ion current, receiving the ion current from the ion source, executing on the ion current a series of filtering steps for detecting a transition, receiving data on the transitions, assigning the transitions associated with peptides into two or more contiguous groups, monitoring, and optionally generating a chromatogram or electropherogram, wherein the microorganism is identified according to the detection of said peptide(s).Type: ApplicationFiled: July 15, 2022Publication date: January 2, 2025Applicants: Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Ecole Normale Superieure de Lyon, Hospices Civils de LyonInventors: Jérôme LEMOINE, Maud GREGSON, Julie GIL, Romain CARRIERE, François VANDENESCH